The White House's draft order for a 100% tariff on select imported drugs signals a major shift in trade policy that could disrupt existing supply chains.
Such tariffs may lead to increased costs for pharmaceutical companies and potentially limit access to essential medications, affecting overall healthcare infrastructure.
Stakeholders in the pharmaceutical and healthcare sectors will need to assess the implications for pricing, availability, and operational logistics as this policy unfolds.